Systemic immune parameters and sleep after ultra-low dose administration of IL-2 in healthy men

Brain, Behavior, and Immunity

Volumn 16, Issue 6, 2002, Pages 663-674

  Lange, Tanja ^a   Marshall, Lisa ^a   Späth Schwalbe, Ernst ^b   Fehm, Horst Lorenz ^a   Born, Jan ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Blood; Cell trafficking; Cytokines; Human; Neuroimmunology

Indexed keywords

CORTICOTROPIN; GAMMA INTERFERON; GROWTH HORMONE; HYDROCORTISONE; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4; INTERLEUKIN 6; PLACEBO; RECOMBINANT PROTEIN; THYROTROPIN;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; DOSE CALCULATION; ENDOCRINE SYSTEM; HEALTH STATUS; HORMONE DETERMINATION; HUMAN; IMMUNE SYSTEM; IMMUNITY; LEUKOCYTE COUNT; LYMPHOCYTE; MALE; MONOCYTE; NATURAL KILLER CELL; NEUTROPHIL; NIGHT; NORMAL HUMAN; POLYSOMNOGRAPHY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; SLEEP; TH2 CELL; TIME;

ADRENOCORTICOTROPIC HORMONE; ADULT; ANALGESICS, NON-NARCOTIC; BLOOD PRESSURE; BODY TEMPERATURE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; HEART RATE; HUMAN GROWTH HORMONE; HUMANS; HYDROCORTISONE; INJECTIONS, SUBCUTANEOUS; INTERFERON TYPE II; INTERLEUKIN-2; INTERLEUKIN-4; INTERLEUKIN-6; LEUKOCYTE COUNT; MALE; NEUROIMMUNOMODULATION; PLATELET COUNT; RECEPTORS, INTERLEUKIN-2; SLEEP; SOLUBILITY;

EID: 12244250147     PISSN: 08891591     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-1591(02)00018-1     Document Type: Article

References (57)

1. Anderson, P. M., & Sorenson, M. A. (1994). Effects of route and formulation on clinical pharmacokinetics of interleukin-2. Clin. Pharmacokinet., 1, 19-31.
2. Bauer, J., Hohagen, F., Gimmel, E., Bruns, F., Lis, S., Krieger, S., Ambach, W., Guthmann, A., Grunze, H., & Fritsch-Montero, R., et al. (1995). Induction of cytokine synthesis and fever suppresses REM sleep and improves mood in patients with major depression. Biol. Psychiatry, 9, 611-621.
3. Benca, R. M., & Quintas, J. (1997). Sleep and host defenses: A review. Sleep, 11, 1027-1037.
4. Bierwolf, C., Struve, K., Marshall, L., Born, J., & Fehm, H. L. (1997). Slow wave sleep drives inhibition of pituitary-adrenal secretion in humans. J. Neuroendocrinol., 6, 479-484.
5. Born, J., Lange, T., Hansen, K., Mölle, M., & Fehm, H. L. (1997). Effects of sleep and circadian rhythm on human circulating immune cells. J. Immunol., 9, 4454-4464.
6. Bukowski, R. M. (1997). Natural history and therapy of metastatic renal cell carcinoma: The role of interleukin-2. Cancer, 7, 1198-1220.
7. Caligiuri, M. A. (1993). Low-dose recombinant interleukin-2 therapy: Rationale and potential clinical applications. Semin. Oncol., 6(Suppl. 9), 3-10.
8. Caraceni, A., Martini, C., Belli, F., Mascheroni, L., Rivoltini, L., Arienti, F., & Cascinelli, N. (1993). Neuropsychological and neurophysiological assessment of the central effects of interleukin-2 administration. Eur. J. Cancer, 9, 1266-1269.
9. Chibowska, M., Krasowska, D., & Weglarz, J. (2001). Pentoxyfilline treatment does not influence the plasma levels of IL-2 and sIL-2R in limited scleroderma patients. Med. Sci. Monit., 2, 282-288.
10. Czerwionka-Szaflarska, M., Chrobot, A., & Szaflarska-Szczepanik, A. (2000). Studies of the effectiveness of interferon alpha treatment for chronic hepatitis C in children. Med. Sci. Monit., 5, 964-970.
11. De Maeyer, E., & De Maeyer-Guignard, J. (1994). Interferons, 15, 265-288.
12. Dickstein, J. B., Moldofsky, H., Lue, F. A., & Hay, J. B. (1999). Intracerebroventricular injection of TNF-α promotes sleep and is recovered in cervical lymph. Am. J. Physiol, 4(Part 2), R1018-R1022.
13. Ettinghausen, S. E., Moore, J. G., White, D. E., Platanias, L., Young, N. S., & Rosenberg, S. A. (1987). Hematologic effects of immunotherapy with lymphokine-activated killer cells and recombinant interleukin-2 in cancer patients. Blood, 6, 1654-1660.
14. Hanisch, U. K., & Quirion, R. (1996). Interleukin-2 as a neuroregulatory cytokine. Brain Res. Brain Res. Rev., 3, 246-284.
15. Hladik, F., Tratkiewicz, J. A., Tilg, H., Vogel, W., Schwulera, U., Kronke, M., Aulitzky, W. E., & Huber, C. (1994). Biologic activity of low dosage IL-2 treatment in vivo. Molecular assessment of cytokine network interaction. J. Immunol., 4, 1449-1454.
16. Jacobson, E. L., Pilaro, F., & Smith, K. A. (1996). Rational interleukin 2 therapy for HIV positive individuals: Daily low doses enhance immune function without toxicity. Proc. Natl. Acad. Sci. USA, 19, 10405-10410.
17. Janke, W., & Debus, G. (1978). Die Eigenschaftswörterliste EWL: Eine mehrdimensionale Methode zur Beschreibung von Aspekten des Befindens.
18. Janssen, R. A., Mulder, N. H., The, T. H., & de Leij, L. (1994). The immunobiological effects of interleukin-2 in vivo. Cancer Immunol. Immunother., 4, 207-216.
19. Karacan, I., Wolff, S. M., Williams, R. L., Hursch, C. J., & Webb, W. B. (1968). The effects of fever on sleep and dream patterns. Psychosomatics, 6, 331-339.
20. Khatri, V. P., Fehniger, T. A., Baiocchi, R. A., Yu, F., Shah, M. H., Schiller, D. S., Gould, M., Gazzinelli, R. T., Bernstein, Z. P., & Caligiuri, M. A. (1998). Ultra low dose interleukin-2 therapy promotes a type 1 cytokine profile in vivo in patients with AIDS and AIDS-associated malignancies. J. Clin. Invest., 6, 1373-1378.
21. Kimura, M., Majde, J. A., Toth, L. A., Opp, M. R., & Krueger, J. M. (1994). Somnogenic effects of rabbit and recombinant human interferons in rabbits. Am. J. Physiol., 1(Part 2), R53-R61.
22. Kintzel, P. E., & Calis, K. A. (1991). Recombinant interleukin-2: A biological response modifier. Clin. Pharm., 2, 110-128.
23. Konrad, M. W., Hemstreet, G., Hersh, E. M., Mansell, P. W., Mertelsmann, R., Kolitz, J. E., & Bradley, E. C. (1990). Pharmacokinetics of recombinant interleukin 2 in humans. Cancer Res., 7, 2009-2017.
24. Kopp, W. C., Holmlund, J. T., & Urba, W. J. (1994). Immunological monitoring and clinical trials of biological response modifiers. Cancer Chemother. Biol. Response Modif., 226-286.
25. Krueger, J. M., Fang, J., Taishi, P., Chen, Z., Kushikata, T., & Gardi, J. (1998). Sleep. A physiologic role for IL-1-β and TNF-α. Ann. NY Acad. Sci., 148-159.
26. Krueger, J. M., Obal, F., Jr., & Fang, J. (1999). Humoral regulation of physiological sleep: Cytokines and GHRH. J. Sleep Res., 53-59.
27. Kushikata, T., Fang, J., Wang, Y., & Krueger, J. M. (1998). Interleukin-4 inhibits spontaneous sleep in rabbits. Am. J. Physiol., 4(Pt. 2), R1185-R1191.
28. Lemmer, B., Schwulera, U., Thrun, A., & Lissner, R. (1992). Circadian rhythm of soluble interleukin-2 receptor in healthy individuals. Eur. Cytokine Netw., 3, 335-336.
29. Lindemann, A., Brossart, P., Hoffken, K., Flasshove, M., Voliotis, D., Diehl, V., Hecker, G., Wagner, H., & Mertelsmann, R. (1993). Immunomodulatory effects of ultra-low-dose interleukin-2 in cancer patients: A phase-IB study. Cancer Immunol. Immunother., 5, 307-315.
30. Lissoni, P. (1997). Effects of low-dose recombinant interleukin-2 in human malignancies. Cancer J. Sci. Am., S115-S120.
31. Lissoni, P., Barni, S., Rovelli, F., Crispino, S., Fumagalli, G., Pescia, S., Vaghi, M., Camesasca, G., & Tancini, G. (1991). Neuroendocrine effects of subcutaneous interleukin-2 injection in cancer patients. Tumori, 3, 212-215.
32. Lissoni, P., Rovelli, F., Brivio, F., Brivio, O., & Fumagalli, L. (1998). Circadian secretions of IL-2, IL-12, IL-6 and IL-10 in relation to the light/dark rhythm of the pineal hormone melatonin in healthy humans. Nat. Immun., 1, 1-5.
33. Lotze, M. T., Matory, Y. L., Ettinghausen, S. E., Rayner, A. A., Sharrow, S. O., Seipp, C. A., Custer, M. C., & Rosenberg, S. A. (1985). In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. J. Immunol., 4, 2865-2875.
34. Mullington, J., Korth, C., Hermann, D. M., Orth, A., Galanos, C., Holsboer, F., & Pollmächer, T. (2000). Dose-dependent effects of endotoxin on human sleep. Am. J. Physiol. Regul. Integr. Comp. Physiol., 4, R947-R955.
35. Nistico, G. (1993). Communications among central nervous system, neuroendocrine and immune systems: Interleukin-2. Prog. Neurobiol., 4, 463-475.
36. Opp, M. R., & Imeri, L. (1999). Sleep as a behavioral model of neuroimmune interactions. Acta Neurobiol. Exp. (Warsz.), 1, 45-53.
37. Petrovsky, N., & Harrison, L. C. (1997). Diurnal rhythmicity of human cytokine production: A dynamic disequilibrium in T helper cell type 1/T helper cell type 2 balance? J. Immunol., 11, 5163-5168.
38. Pollmächer, T., Schreiber, W., Gudewill, S., Vedder, H., Fassbender, K., Wiedemann, K., Trachsel, L., Galanos, C., & Holsboer, F. (1993). Influence of endotoxin on nocturnal sleep in humans. Am. J. Physiol., 6(Part 2), R1077-R1083.
39. Pozniak, M. A., Christy, P. S., Albertini, M. R., Duffek, S. M., & Schiller, J. H. (1995). Interleukin-2-induced splenic enlargement. Cancer, 11, 2737-2741.
40. Raab, C., Weidmann, E., Schmidt, A., Bergmann, L., Badenhoop, K., Usadel, K. H., & Haak, T. (1999). The effects of interleukin-2 treatment on endothelin and the activation of the hypothalamic-pituitary-adrenal axis. Clin. Endocrinol. (Oxf.), 1, 37-44.
41. Rasko, J.E.J., & Gogh, N.M. (1994). Granulocyte-Macrophage Colony Stimulating Factor 19, 343-369.
42. Rechtschaffen, A., & Kales, A. (1968). A Manual of Standardized Terminology, Techniques and Scoring System for Sleep of Human Subjects.
43. Salvo, G., Samoggia, P., Masciulli, R., Boccoli, G., Allavena, P., Mariani, G., Bullo, A., Montesoro, E., Bulgarini, D., & Carlini, P. (1992). Interleukin-2 bolus therapy induces immediate and selective disappearance from peripheral blood of all lymphocyte subpopulations displaying natural killer activity: Role of cell adhesion to endothelium. Eur. J. Cancer, 4-5, 818-825.
44. Sarna, G., Machleder, H., Collins, J., Bonavida, B., Jacobs, E., Hawkins, R., Golub, S., Shau, H., Fahey, J., & Popow, J. (1994). A comparative study of intravenous versus intralymphatic interleukin-2, with assessment of effects of interleukin-2 on both peripheral blood and thoracic-duct lymph. J. Immunother. Emphasis. Tumor Immunol., 2, 140-146.
45. Shearer, W. T., Reuben, J. M., Mullington, J. M., Price, N. J., Lee, B. N., Smith, E. O., Szuba, M. P., Van Dongen, H. P., & Dinges, D. F. (2001). Soluble TNF-alpha receptor 1 and IL-6 plasma levels in humans subjected to the sleep deprivation model of spaceflight. J. Allergy Clin. Immunol., 1, 165-170.
46. Smith, K. A. (1993). Lowest dose interleukin-2 immunotherapy. Blood, 6, 1414-1423.
47. Späth-Schwalbe, E., Hansen, K., Schmidt, F., Schrezenmeier, H., Marshall, L., Burger, K., Fehin, H. L., & Born, J. (1998). Acute effects of recombinant human interleukin-6 on endocrine and central nervous sleep functions in healthy men. J. Clin. Endocrinol. Metab., 5, 1573-1579.
48. Späth-Schwalbe, E., Lange, T., Perras, B., Fehm, H. L., & Born, J. (2000). Interferon-α acutely impairs sleep in healthy humans. Cytokine, 5, 518-521.
49. Sundin, D. J., & Wolin, M. J. (1998). Toxicity management in patients receiving low-dose aldesleukin therapy. Ann. Pharmacother., 12, 1344-1352.
50. Toth, L. A. (1995). Sleep, sleep deprivation and infectious disease: Studies in animals. Adv. Neuroimmunol., 1, 79-92.
51. Toth, L. A., Tolley, E. A., & Krueger, J. M. (1993). Sleep as a prognostic indicator during infectious disease in rabbits. Proc. Soc. Exp. Biol. Med., 2, 179-192.
52. Trachsel, L., Schreiber, W., Holsboer, F., & Pollmächer, T. (1994). Endotoxin enhances EEG alpha and beta power in human sleep. Sleep, 2, 132-139.
53. Tritarelli, E., Rocca, E., Testa, U., Boccoli, G., Camagna, A., Calabresi, F., & Peschle, C. (1991). Adoptive immunotherapy with high-dose interleukin-2: Kinetics of circulating progenitors correlate with interleukin-6, granulocyte colony-stimulating factor level. Blood, 4, 741-749.
54. Voss, S. D., Hank, J. A., Nobis, C. A., Fisch, P., Sosman, J. A., & Sondel, P. M. (1989). Serum levels of the low-affinity interleukin-2 receptor molecule (TAG) during IL-2 therapy reflect systemic lymphoid mass activation. Cancer Immunol. Immunother., 4, 261-269.
55. Whittington, R., & Faulds, D. (1993). Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer. Drugs, 3, 446-514.
56. Young, M. R., Matthews, J. P., Kanabrocki, E. L., Sothern, R. B., Roitman-Johnson, B., & Scheving, L. E. (1995). Circadian rhythmometry of serum interleukin-2, interleukin-10, tumor necrosis factor-α, and granulocyte-macrophage colony-stimulating factor in men. Chronobiol. Int., 1, 19-27.
57. Zou, W., Foussat, A., Houhou, S., Durand-Gasselin, I., Dulioust, A., Bouchet, L., Galanaud, P., Levy, Y., & Emilie, D. (1999). Acute upregulation of CCR-5 expression by CD4+ T lymphocytes in HIV-infected patients treated with interleukin-2. ANRS 048 IL-2 Study Group. AIDS, 4, 455-463.